NCT04444167 - A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 7, 2020

Primary Completion Date

November 20, 2023

Study Completion Date

November 20, 2023

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL

AK104

Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months

DRUG

Lenvatinib

Subjects will receive AK104 and lenvatinib until disease progression for a maximum of 24 months

Trial Locations (1)

Chinese PLA General Hospital, Beijing